vs
Apellis Pharmaceuticals, Inc.（APLS）与GLACIER BANCORP, INC.（GBCI）财务数据对比。点击上方公司名可切换其他公司
GLACIER BANCORP, INC.的季度营收约是Apellis Pharmaceuticals, Inc.的1.5倍（$306.8M vs $199.9M），GLACIER BANCORP, INC.净利率更高（26.8% vs -29.5%，领先56.3%），过去两年GLACIER BANCORP, INC.的营收复合增速更高（24.3% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Glacier Bancorp, Inc.是美国区域性多银行控股公司，总部位于蒙大拿州卡利斯佩尔，前身为1990年在特拉华州注册成立的企业。集团面向个人及商业客户提供各类银行服务，在全美8个州共设有221个营业网点。
APLS vs GBCI — 直观对比
营收规模更大
GBCI
是对方的1.5倍
$199.9M
净利率更高
GBCI
高出56.3%
-29.5%
两年增速更快
GBCI
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $306.8M |
| 净利润 | $-59.0M | $82.1M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 26.8% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSGBCI
| Q1 26 | — | $306.8M | ||
| Q4 25 | $199.9M | $306.5M | ||
| Q3 25 | $458.6M | $260.7M | ||
| Q2 25 | $178.5M | $240.6M | ||
| Q1 25 | $166.8M | $222.6M | ||
| Q4 24 | $212.5M | $223.0M | ||
| Q3 24 | $196.8M | $214.9M | ||
| Q2 24 | $199.7M | $198.7M |
净利润APLSGBCI
| Q1 26 | — | $82.1M | ||
| Q4 25 | $-59.0M | $63.8M | ||
| Q3 25 | $215.7M | $67.9M | ||
| Q2 25 | $-42.2M | $52.8M | ||
| Q1 25 | $-92.2M | $54.6M | ||
| Q4 24 | $-36.4M | $61.8M | ||
| Q3 24 | $-57.4M | $51.1M | ||
| Q2 24 | $-37.7M | $44.7M |
营业利润率APLSGBCI
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 24.9% | ||
| Q3 25 | 48.7% | 32.7% | ||
| Q2 25 | -18.6% | 27.1% | ||
| Q1 25 | -50.0% | 28.5% | ||
| Q4 24 | -12.3% | 33.0% | ||
| Q3 24 | -24.0% | 28.9% | ||
| Q2 24 | -14.7% | 27.3% |
净利率APLSGBCI
| Q1 26 | — | 26.8% | ||
| Q4 25 | -29.5% | 20.8% | ||
| Q3 25 | 47.0% | 26.0% | ||
| Q2 25 | -23.6% | 21.9% | ||
| Q1 25 | -55.3% | 24.5% | ||
| Q4 24 | -17.1% | 27.7% | ||
| Q3 24 | -29.2% | 23.8% | ||
| Q2 24 | -18.9% | 22.5% |
每股收益（稀释后）APLSGBCI
| Q1 26 | — | $0.63 | ||
| Q4 25 | $-0.40 | $0.49 | ||
| Q3 25 | $1.67 | $0.57 | ||
| Q2 25 | $-0.33 | $0.45 | ||
| Q1 25 | $-0.74 | $0.48 | ||
| Q4 24 | $-0.30 | $0.55 | ||
| Q3 24 | $-0.46 | $0.45 | ||
| Q2 24 | $-0.30 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $4.2B |
| 总资产 | $1.1B | $31.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSGBCI
| Q1 26 | — | $1.4B | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
股东权益APLSGBCI
| Q1 26 | — | $4.2B | ||
| Q4 25 | $370.1M | $4.2B | ||
| Q3 25 | $401.2M | $3.6B | ||
| Q2 25 | $156.3M | $3.5B | ||
| Q1 25 | $164.2M | $3.3B | ||
| Q4 24 | $228.5M | $3.2B | ||
| Q3 24 | $237.1M | $3.2B | ||
| Q2 24 | $264.3M | $3.1B |
总资产APLSGBCI
| Q1 26 | — | $31.7B | ||
| Q4 25 | $1.1B | $32.0B | ||
| Q3 25 | $1.1B | $29.0B | ||
| Q2 25 | $821.4M | $29.0B | ||
| Q1 25 | $807.3M | $27.9B | ||
| Q4 24 | $885.1M | $27.9B | ||
| Q3 24 | $901.9M | $28.2B | ||
| Q2 24 | $904.5M | $27.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSGBCI
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $374.4M | ||
| Q3 25 | $108.5M | $112.4M | ||
| Q2 25 | $4.4M | $86.0M | ||
| Q1 25 | $-53.4M | $52.4M | ||
| Q4 24 | $19.4M | $258.0M | ||
| Q3 24 | $34.1M | $150.1M | ||
| Q2 24 | $-8.3M | $62.7M |
自由现金流APLSGBCI
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $347.6M | ||
| Q3 25 | $108.3M | $104.8M | ||
| Q2 25 | $4.4M | $79.5M | ||
| Q1 25 | $-53.4M | $46.8M | ||
| Q4 24 | $19.3M | $209.8M | ||
| Q3 24 | — | $137.7M | ||
| Q2 24 | $-8.4M | $44.1M |
自由现金流率APLSGBCI
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 113.4% | ||
| Q3 25 | 23.6% | 40.2% | ||
| Q2 25 | 2.5% | 33.1% | ||
| Q1 25 | -32.0% | 21.0% | ||
| Q4 24 | 9.1% | 94.1% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | -4.2% | 22.2% |
资本支出强度APLSGBCI
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 8.8% | ||
| Q3 25 | 0.0% | 2.9% | ||
| Q2 25 | 0.0% | 2.7% | ||
| Q1 25 | 0.0% | 2.5% | ||
| Q4 24 | 0.0% | 21.6% | ||
| Q3 24 | 0.0% | 5.8% | ||
| Q2 24 | 0.0% | 9.3% |
现金转化率APLSGBCI
| Q1 26 | — | — | ||
| Q4 25 | — | 5.87× | ||
| Q3 25 | 0.50× | 1.66× | ||
| Q2 25 | — | 1.63× | ||
| Q1 25 | — | 0.96× | ||
| Q4 24 | — | 4.18× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 1.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
GBCI
| Net Interest Income | $268.7M | 88% |
| Noninterest Income | $38.1M | 12% |
